Key Insights

Highlights

Success Rate

61% trial completion

Published Results

14 trials with published results (42%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

21.2%

7 terminated out of 33 trials

Success Rate

61.1%

-25.4% vs benchmark

Late-Stage Pipeline

9%

3 trials in Phase 3/4

Results Transparency

127%

14 of 11 completed with results

Key Signals

14 with results61% success

Data Visualizations

Phase Distribution

31Total
Not Applicable (6)
P 1 (9)
P 2 (13)
P 3 (3)

Trial Status

Completed11
Active Not Recruiting7
Terminated7
Recruiting6
Withdrawn1
Not Yet Recruiting1

Trial Success Rate

61.1%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (33)

Showing 20 of 20 trials
NCT06745024Phase 3Active Not RecruitingPrimary

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

NCT03793166Phase 3Active Not Recruiting

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

NCT04071236Phase 1Recruiting

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

NCT02364557Phase 2Completed

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NCT04693377Not ApplicableRecruiting

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

NCT06982222Phase 1Not Yet Recruiting

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

NCT04071223Phase 2Active Not Recruiting

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

NCT02306161Phase 3Active Not Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

NCT04090398Phase 2Active Not Recruiting

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

NCT04489719Recruiting

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

NCT04754425Phase 2Terminated

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

NCT03796767Phase 2Active Not Recruiting

Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

NCT01050504Recruiting

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

NCT05924672Phase 2Active Not Recruiting

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

NCT02699697Not ApplicableCompleted

Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis

NCT04616547Phase 2Terminated

Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

NCT06549478Phase 1RecruitingPrimary

Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases

NCT03858205Not ApplicableRecruiting

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

NCT03691493Phase 2Completed

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

NCT03204812Phase 2Completed

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Scroll to load more

Research Network

Activity Timeline